Erratum: Malignant fibrous histiocytoma-pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study (Langenbeck's Archives of Surgery (2009) 589 (DOI: 10.1007/s00423-009-0465-0));Malignant fibrous histiocytoma-pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study

Langenbeck's Archives of Surgery

Volumn 395, Issue 3, 2010, Pages 261-275

  Adrien, Daigeler ^a   Ludger, Klein Hitpass ^b   Ingo, Stricker ^a   Oliver, Müller ^c   Cornelius, Kuhnen ^a   Michael, Chromik Ansgar ^d   Lars, Steinstraesser ^a   Ole, Goertz ^a   Hans Ulrich, Steinau ^a   Marcus, Lehnhardt ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^d ST JOSEF HOSPITAL   (Germany)

Author keywords

Gene expression profiling; Malignant fibrous histiocytoma; MFH; NOS sarcoma; Pleomorphic sarcoma

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 3; ALPHA7 INTEGRIN; ANGIOTENSIN 1 RECEPTOR; APOLIPOPROTEIN C1; APOLIPOPROTEIN E; BIGLYCAN; CARBONATE DEHYDRATASE XII; CAVEOLIN 3; CD36 ANTIGEN; CONNECTIN; CYSTATIN; CYSTATIN F; ENOLASE; ENOLASE 3; EPHRIN RECEPTOR B2; FIBRILLIN 1; GLUTAMINASE; LIPOPROTEIN LIPASE; MATRIX METALLOPROTEINASE 16; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 7; NEBULIN; PEROXIREDOXIN 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLECKSTRIN; PLEIOTROPHIN; POTASSIUM CHANNEL KV1.1; PROTEIN SH3; SOMATOMEDIN BINDING PROTEIN 5; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MICROARRAY ANALYSIS; PILOT STUDY; PLEOMORPHIC SARCOMA; PRIORITY JOURNAL; PROGNOSIS; SARCOMA; TUMOR CLASSIFICATION; TUMOR VOLUME; UPREGULATION; DNA MICROARRAY; GENETICS; LIPOSARCOMA; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; LIPOSARCOMA; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS;

EID: 77954668513     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-009-0474-z     Document Type: Erratum

References (86)

1. Poremba C (2006) Soft tissue sarcomas: the role of histology and molecular pathology for differential diagnosis. Verh Dtsch Ges Pathol 90:59-72
2. Lehnhardt M, Daigeler A, Homann HH et al (2008) MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities-an analysis of 140 patients. Langenbecks Arch Surg. doi:10.1007/s00423-008-0368-5
3. Fletcher CD (1992) Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16:213-228
4. Fletcher CD, Gustafson P, Rydholm A et al (2001) Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol 19:3045-3050
5. Hollowood K, Fletcher CD (1995) Malignant fibrous histiocytoma: morphologic pattern or pathologic entity. Semin Diagn Pathol 12:210-220
6. Massi D, Beltrami G, Capanna R et al (2004) Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance. Eur J Surg Oncol 30:1131-1136. doi:10.1016/j. ejso.2004.07.018
7. Fletcher CD (2006) The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 48:3-12. doi:10.1111/j.1365-2559.2005.02284.x
8. Randall RL, Albritton KH, Ferney BJ et al (2004) Malignant fibrous histiocytoma of soft tissue: an abandoned diagnosis. Am J Orthop 33:602-608. doi:10.1007/s00132-004-0667-7 (Pubitemid 39462748)
9. Nakayama R, Nemoto T, Takahashi H et al (2007) Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20:749-759. doi:10.1038/modpathol.3800794 (Pubitemid 46933446)
10. Lee YF, John M, Edwards S et al (2003) Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer 88:510-515. doi:10.1038/sj.bjc.6600766 (Pubitemid 36363359)
11. Nielsen TO, West RB, Linn SC et al (2002) Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359:1301-1307. doi:10.1016/S0140-6736(02)08270-3 (Pubitemid 34310636)
12. Segal NH, Pavlidis P, Antonescu CR et al (2003) Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 163:691-700
13. Schofield D, Triche TJ (2002) cDNA microarray analysis of global gene expression in sarcomas. Curr Opin Oncol 14:406-411. doi:10.1097/00001622- 200207000-00007 (Pubitemid 34747976)
14. Backes C, Keller A, Kuentzer J et al (2007) GeneTrail-advanced gene set enrichment analysis. Nucleic Acids Res 35:W186-W192. doi:10.1093/nar/gkm323
15. Beissbarth T, Speed TP (2004) GOstat: find statistically overrepresented gene ontologies within a group of genes. Bioinformatics 6:1464-1465. doi:10.1093/bioinformatics/bth088 (Pubitemid 38931420)
16. Detwiller KY, Fernando NT, Segal NH et al (2005) Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 65:5881-5889. doi:10.1158/0008-5472.CAN-04-4078 (Pubitemid 40911194)
17. Yoon SS, Segal NH, Park PJ et al (2006) Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res 135:282-290. doi:10.1016/j.jss.2006.01.023 (Pubitemid 44414877)
18. Weitz J, Antonescu CR, Brennan MF (2003) Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 21:2719-2725. doi:10.1200/ JCO.2003.02.026
19. Oda Y, Tamiya S, Oshiro Y et al (2002) Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathol Int 52:595-606. doi:10.1046/j.1440- 1827.2002.01399.x
20. Matsumoto S, Ahmed AR, Kawaguchi N et al (2003) Results of surgery for malignant fibrous histiocytomas of soft tissue. Int J Clin Oncol 8:104-109. doi:10.1007/s101470300018 (Pubitemid 36548479)
21. Belal A, Kandil A, Allam A et al (2002) Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol 25:16-22. doi:10.1097/00000421-200202000-00003 (Pubitemid 34131022)
22. Dei Tos A (2006) Classification of pleomorphic sarcoma: where are we now? Histopathology 48:51-62. doi:10.1111/j.1365- 2559.2005.02289.x
23. Skubitz KM, D'Adamo DR (2007) Sarcoma. Mayo Clin Proc 82:1409-1432
24. Skubitz KM, Skubitz AP (2004) Role of gene expression arrays in sarcomas. Curr Oncol Rep 6:309-314. doi:10.1007/s11912-004- 0041-42
25. Baird K, Davis S, Antonescu CR et al (2005) Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65:9226-9235. doi:10.1158/0008-5472.CAN-05-1699 (Pubitemid 41507988)
26. Nagayama S, Katagiri T, Tsunoda T et al (2002) Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 62:5859-5866 (Pubitemid 35204746)
27. Lee YF, John M, Falconer A et al (2004) A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Res 64:7201-7204. doi:10.1158/0008-5472. CAN-04-1673
28. West RB, Harvell J, Linn SC et al (2004) Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol 28:1063-1069. doi:10.1097/01.pas.0000126857. 86186.4c
29. Schaefer KL, Brachwitz K, Wai DH et al (2004) Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. Cancer Res 64:3395-3405. doi:10.1158/0008-5472.CAN-03-0809 (Pubitemid 38657911)
30. Skubitz KM, Cheng EY, Clohisy DR et al (2005) Differential gene expression in liposarcoma, lipoma, and adipose tissue. Cancer Invest 23:105-118. doi:10.1081/CNV-50432
31. Goransson M, Elias E, Stahlberg A et al (2005) Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP betamediated interleukin 6 expression. Int J Cancer 115:556-560. doi:10.1002/ijc.20893
32. Fritz B, Schubert F, Wrobel G et al (2002) Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 62:2993-2998
33. Italiano A, Cardot N, Dupre F et al (2007) Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the "missing link" between lipomas and liposarcomas? Int J Cancer 121:308-315. doi:10.1002/ijc.22685
34. Bassett MD, Schuetze SM, Disteche C et al (2005) Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognostication. Cancer 103:409-416. doi:10.1002/cncr.20779
35. Meis-Kindblom JM, Sjogren H, Kindblom LG et al (2001) Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis. Virchows Arch 439:141-151. doi:10.1007/ s004280100423
36. Sandberg AA (2004) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet 155:1-24. doi:10.1016/j.cancergencyto.2004.08.005
37. Engstrom K, Willen H, Kabjorn-Gustafsson C et al (2006) The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol 168:1642-1653. doi:10.2353/ajpath.2006.050872
38. Szymanska J, Virolainen M, Tarkkanen M et al (1997) Overrepresentation of 1q21-23 and 12q13-21 in lipoma-like liposarcomas but not in benign lipomas: a comparative genomic hybridization study. Cancer Genet Cytogenet 99:14-18. doi:10.1016/S0165- 4608(96)00436-440
39. Fukukawa C, Nakamura Y, Katagiri T (2005) Molecular target therapy for synovial sarcoma. Future Oncol 1:805-812. doi:10.2217/14796694.1.6.805
40. Ishibe T, Nakayama T, Okamoto T et al (2005) Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res 11:2702-2712. doi:10.1158/1078-0432.CCR-04-2057
41. Lubieniecka JM, Nielsen TO (2005) cDNA microarray-based translational research in soft tissue sarcoma. J Surg Oncol 92:267-271. doi:10.1002/jso.20409
42. Nagayama S, Fukukawa C, Katagiri T et al (2005) Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene 24:6201-6212. doi:10.1038/sj. onc.1208780
43. Singer S, Socci ND, Ambrosini G et al (2007) Gene expression profiling of liposarcoma identifies distinct biological types/ subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 67:6626-6636. doi:10.1158/0008-5472.CAN-07-0584
44. Gazziola C, Cordani N, Wasserman B et al (2003) Malignant fibrous histiocytoma: a proposed cellular origin and identification of its characterizing gene transcripts. Int J Oncol 23:343-351
45. Wang M, Liu YE, Greene J et al (1997) Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 14:2767-2774. doi:10.1038/sj.onc.1201245
46. Alford SH, Vrana MS, Waite L et al (2007) Matrix metalloproteinase expression in high grade soft tissue sarcomas. Oncol Rep 18:1529-1536
47. Roebuck MM, Helliwell TR, Chaudhry IH et al (2005) Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities. Am J Clin Pathol 123:405-414. doi:10.1309/ LK1V7R99JL41WVKP
48. Partridge JJ, Madsen MA, Ardi VC et al (2007) Functional analysis of matrix metalloproteinases and tissue inhibitors of metalloproteinases differentially expressed by variants of human HT-1080 fibrosarcoma exhibiting high and low levels of intravasation and metastasis. J Biol Chem 282:35964-35977. doi:10.1074/jbc.M705993200
49. Sun BC, Sun Y, Zhao XL et al (2006) Correlation between matrix metalloproteinases-2 and tissue inhibitor of metalloproteinase-2 expression, metastatic potential and tumor angiogenesis in synovial sarcoma and its prognostic significance. Chung-hua Ping Li Hsueh Tsa Chih 35:155-158
50. Wittmann S, Wunder C, Zirn B et al (2008) New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer 47:386-395. doi:10.1002/gcc.20544
51. Shang C, Fu WN, Guo Y et al (2007) Study of the SH3-domain GRB2-like 2 gene expression in laryngeal carcinoma. Chin Med J (Engl) 120:385-388
52. Li X, Cao X, Zhang W et al (2007) Expression level of insulinlike growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci 98:1592-1596. doi:10.1111/j.1349- 7006.2007.00565.x
53. Wang H, Arun BK, Fuller GN et al (2008) IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 14:261-267. doi:10.1111/j.1524- 4741.2008.00572.x
54. Hung PS, Kao SY, Shih YH et al (2008) Insulin-like growth factor binding protein-5 (IGFBP-5) suppresses the tumourigenesis of head and neck squamous cell carcinoma. J Pathol 214:368-376. doi:10.1002/path.2280
55. Umemura A, Itoh Y, Itoh K et al (2008) Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. Hepatology 47:493-502. doi:10.1002/hep.22027
56. Yu Y, Chen W, Zhang Y et al (2007) Suppression of salivary adenoid cystic carcinoma growth and metastasis by ErbB3 binding protein Ebp1 gene transfer. Int J Cancer 120:1909-1913. doi:10.1002/ijc.22541
57. Yamazaki H, Handa A, Nishi M et al (2004) Ribozyme mediated down-regulation of thrombospondin receptor CD36 inhibits the growth of the human osteosarcoma cell line. Oncol Rep 11:371-374
58. Chen M, Pych E, Corpron C et al (2002) Regulation of CD36 expression in human melanoma cells. Adv Exp Med Biol 507:337-342
59. Galeza-Kulik M, Zebracka J, Szpak-Ulczok S et al (2006) Expression of selected genes involved in transport of ions in papillary thyroid carcinoma. Endokrynol Pol 57:26-31
60. Noguchi Y, Nomura K, Yoshikawa T et al (1996) Role of insulin resistance in decreasing lipoprotein lipase activity in tumorbearing rats. Surg Today 26:271-275. doi:10.1007/BF00311587
61. Noguchi Y, Vydelingum NA, Younes RN et al (1991) Tumorinduced alterations in tissue lipoprotein lipase activity and mRNA levels. Cancer Res 51:863-869
62. Sakayama K, Masuno H, Miyazaki T et al (1994) Existence of lipoprotein lipase in human sarcomas and carcinomas. Jpn J Cancer Res 85:515-521
63. Yu YP, Yu G, Tseng G et al (2007) Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 67:8043-8050. doi:10.1158/0008-5472.CAN-07-0648
64. Liestol K, Kvittingen EA, Rootwelt H et al (2000) Association between apolipoprotein E genotypes and cancer risk in patients with acquired immunodeficiency syndrome. Cancer Detect Prev 24:496-499
65. Browning PJ, Roberts DD, Zabrenetzky V et al (1994) Apolipoprotein E (ApoE), a novel heparin-binding protein inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice. J Exp Med 180:1949-1954. doi:10.1084/jem.180.5.1949
66. Oue N, Hamai Y, Mitani Y, et al (2004) Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 64:2397-2405. doi:10.1158/0008-5472.CAN-03-3514
67. Wright KO, Messing EM, Reeder JE (2002) Increased expression of the acid sphingomyelinase-like protein ASML3a in bladder tumors. J Urol 168:2645-2649. doi:10.1016/S0022-5347(05) 64236-X
68. Agaimy A, Gaumann A, Schroeder J et al (2007) Primary and metastatic high-grade pleomorphic sarcoma/malignant fibrous histiocytoma of the gastrointestinal tract: an approach to the differential diagnosis in a series of five cases with emphasis on myofibroblastic differentiation. Virchows Arch 451:949-957. doi:10.1007/s00428-007-0495-3
69. Yamamoto T, Akisue T, Marui T et al (2003) Immunohistochemical analysis of platelet-derived growth factor and its receptors in soft tissuemalignant fibrous histiocytoma. Anticancer Res 23:4325-4328
70. Irsan I, Akisue T, Hara H et al (2007) Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. Anticancer Res 27:423-429
71. Kawamoto T, Akisue T, Marui T et al (2004) Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines. Anticancer Res 24:2675-2679
72. Ito S, Nemoto T, Satoh S et al (2000) Human rhabdomyosarcoma cells retain insulin-regulated glucose transport activity through glucose transporter 1. Arch Biochem Biophys 373:72-82. doi:10.1006/abbi.1999.1535
73. Thomas DM, Maher F, Rogers SD et al (1996) Expression and regulation by insulin of GLUT 3 in UMR 106-01, a clonal rat osteosarcoma cell line. Biochem Biophys Res Commun 218:789-793. doi:10.1006/bbrc.1996.0140
74. Baer S, Casaubon L, Schwartz MR et al (2002) Glut3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival. Laryngoscope 112:393-396. doi:10.1097/ 00005537-200202000-200300034
75. Walters DK, Steinmann P, Langsam B et al (2008) Identification of potential chemoresistance genes in osteosarcoma. Anticancer Res 28:673-679
76. Wu H, Barusevicius A, Babb J et al (2005) Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J Cutan Pathol 32:125-130. doi:10.1111/ j.0303-6987.2005.00282.x
77. Hatakeyama S, Ohyama C, Minagawa S et al (2004) Functional correlation of trophinin expression with the malignancy of testicular germ cell tumor. Cancer Res 64:4257-4262. doi:10.1158/0008-5472.CAN-04-0732
78. Harada O, Suga T, Suzuki T et al (2007) The role of trophinin, an adhesion molecule unique to human trophoblasts, in progression of colorectal cancer. Int J Cancer 121:1072-1078. doi:10.1002/ ijc.22821
79. Chen KY, Lee YC, Lai JM et al (2007) Identification of trophinin as an enhancer for cell invasion and a prognostic factor for early stage lung cancer. Eur J Cancer 43:782-790. doi:10.1016/j. ejca.2006.09.029
80. Groth S, Schulze M, Kalthoff H et al (2005) Adhesion and Rac1- dependent regulation of biglycan gene expression by transforming growth factor-beta. Evidence for oxidative signaling through NADPH oxidase. J Biol Chem 280:33190-33199. doi:10.1074/ jbc.M504249200
81. Valladares A, Hernandez NG, Gomez FS et al (2006) Genetic expression profiles and chromosomal alterations in sporadic breast cancer in Mexican women. Cancer Genet Cytogenet 170:147-151. doi:10.1016/j.cancergencyto.2006.06.002
82. Leivo I, Jee KJ, Heikinheimo K et al (2005) Characterization of gene expression in major types of salivary gland carcinomas with epithelial differentiation. Cancer Genet Cytogenet 156:104-113. doi:10.1016/j. cancergencyto.2004.04.016
83. Sato H, Okada Y, Seiki M (1997) Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Thromb Haemost 78:497-500
84. Gilles C, Polette M, Seiki M et al (1997) Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest 76:651-660
85. Ohnishi Y, Tajima S, Ishibashi A (2001) Coordinate expression of membrane type-matrix metalloproteinases-2 and 3 (MT2-MMP and MT3-MMP) and matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells. Eur J Dermatol 11:420-423
86. Sun YN, Li Y (2004) Expression of mRNA for membrane-type 1, 2, and 3 matrix metalloproteinases in human laryngeal cancer. Chin Med Sci J 19:170-173